6-imidazo[1,2-a]pyridin-3-yl-N-pyrrolidin-3-ylpyridin-2-amine | 1044733-31-4

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 咪唑并吡啶类
• 英文名称: 6-imidazo[1,2-a]pyridin-3-yl-N-pyrrolidin-3-ylpyridin-2-amine
• CAS: 1044733-31-4
• 化学式: C₁₆H₁₇N₅
• 分子量: 279.344
• InChiKey: LSPAZTAZPMMNBM-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.5
• 重原子数：
  21
• 可旋转键数：
  3
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.25
• 拓扑面积：
  54.2
• 氢给体数：
  2
• 氢受体数：
  4

反应信息

• 作为产物：
  描述：

  Tert-butyl 3-[(6-imidazo[1,2-a]pyridin-3-ylpyridin-2-yl)amino]pyrrolidine-1-carboxylate 在 盐酸 作用下， 以 乙醚 、 二氯甲烷 为溶剂， 生成 6-imidazo[1,2-a]pyridin-3-yl-N-pyrrolidin-3-ylpyridin-2-amine
  参考文献：
  名称：

  IRAK-4抑制剂。第三部分：一系列咪唑并[1,2-a]吡啶。

  摘要：

  通过常规的项目交叉筛选鉴定出有效的IRAK抑制剂后，建立了新型的IRAK-4抑制剂。探索了咪唑并[1,2-a]吡啶基吡啶和苯并咪唑并吡啶的SAR。

  DOI：

  10.1016/j.bmcl.2008.04.042

文献信息

• [EN] MULTI-CYCLIC IRAK AND FLT3 INHIBITING COMPOUNDS AND USES THEREOF<br/>[FR] COMPOSÉS MULTI-CYCLIQUES INHIBITEURS DE FLT3 ET IRAK ET LEURS UTILISATIONS
  申请人：CHILDRENS HOSPITAL MED CT

  公开号：WO2022026935A1

  公开（公告）日：2022-02-03

  Some embodiments of the disclosure include disclosed compounds (e.g., compounds of Formula (I)) and compositions (e.g., pharmaceutical compositions) which inhibit IRAK and/or FLT3 and which can be used for treating, for example, certain diseases. Some embodiments include methods of using the disclosed compound (e.g., in compositions or in pharmaceutical compositions) for administering and treating (e.g., diseases such as hematopoietic cancers, myelodysplastic syndromes (MDS), acute myeloid leukemia (AML), etc.). Additional embodiments provide disease treatment using combinations of the disclosed IRAK and/or FLT3 inhibiting compounds with other therapies, such as cancer therapies.

  一些实施例包括披露的化合物（例如，Formula（I）的化合物）和组合物（例如，药物组合物），其抑制IRAK和/或FLT3，可用于治疗某些疾病。一些实施例包括使用披露的化合物的方法（例如，在组合物或药物组合物中）用于给药和治疗（例如，血液系统癌症、骨髓增生异常综合征（MDS）、急性髓系白血病（AML）等疾病）。其他实施例提供使用披露的IRAK和/或FLT3抑制化合物与其他疗法（例如癌症治疗）的组合进行疾病治疗。
• IMIDAZO[1,2-A]PYRIDINE COMPOUNDS, COMPOSITIONS COMPRISING THEM, METHODS FOR TREATING DISEASES USING THEM, AND METHODS FOR PREPARING THEM
  申请人：Children's Hospital Medical Center

  公开号：EP3854796A1

  公开（公告）日：2021-07-28

  Some embodiments of the invention include inventive compounds (e.g., compounds of Formula (I)). Other embodiments include compositions (e.g., pharmaceutical compositions) comprising the inventive compound. Still other embodiments of the invention include compositions (e.g., pharmaceutical compositions) for treating, for example, certain diseases using the inventive compounds. Some embodiments include methods of using the inventive compound (e.g., in compositions or in pharmaceutical compositions) for administering and treating (e.g., diseases such as cancer or blood disorders). Further embodiments include methods for making the inventive compounds. Additional embodiments of the invention are also discussed herein.

  本发明的一些实施方案包括本发明化合物（如式（I）化合物）。其它实施方案包括包含本发明化合物的组合物（如药物组合物）。本发明的另一些实施方案包括使用本发明化合物治疗例如某些疾病的组合物（例如药物组合物）。一些实施方案包括使用本发明化合物（例如在组合物中或在药物组合物中）施用和治疗（例如癌症或血液疾病等疾病）的方法。进一步的实施方案包括制造本发明化合物的方法。本文还讨论了本发明的其它实施方案。
• Substituted imidazo[1,2-A]pyridines as IRAK 1/4 and flt3 inhibitors
  申请人：CHILDREN'S HOSPITAL MEDICAL CENTER

  公开号：US11254667B2

  公开（公告）日：2022-02-22

  Some embodiments of the invention include inventive compounds (e.g., compounds of Formula (I)). Other embodiments include compositions (e.g., pharmaceutical compositions) comprising the inventive compound. Still other embodiments of the invention include compositions (e.g., pharmaceutical compositions) for treating, for example, certain diseases using the inventive compounds. Some embodiments include methods of using the inventive compound (e.g., in compositions or in pharmaceutical compositions) for administering and treating (e.g., diseases such as cancer or blood disorders). Further embodiments include methods for making the inventive compounds. Additional embodiments of the invention are also discussed herein.

  本发明的一些实施方案包括本发明化合物（如式（I）化合物）。其它实施方案包括包含本发明化合物的组合物（如药物组合物）。本发明的另一些实施方案包括使用本发明化合物治疗例如某些疾病的组合物（例如药物组合物）。一些实施方案包括使用本发明化合物（例如在组合物中或在药物组合物中）施用和治疗（例如癌症或血液疾病等疾病）的方法。进一步的实施方案包括制造本发明化合物的方法。本文还讨论了本发明的其它实施方案。
• IMIDAZO[1,2-A]PYRIDIN COMPOUNDS, COMPOSITIONS COMPRISING THEM, METHODS FOR TREATING DISEASES USING THEM, AND METHODS FOR PREPARING THEM
  申请人：Children's Hospital Medical Center

  公开号：EP3500571B1

  公开（公告）日：2020-12-30
• COMPOUNDS, COMPOSITIONS, METHODS FOR TREATING DISEASES, AND METHODS FOR PREPARING COMPOUNDS
  申请人：CHILDREN'S HOSPITAL MEDICAL CENTER

  公开号：US20200199123A1

  公开（公告）日：2020-06-25

  Some embodiments of the invention include inventive compounds (e.g., compounds of Formula (I)) and compositions (e.g., pharmaceutical compositions) which can be used for treating, for example, certain diseases. Some embodiments include methods of using the inventive compound (e.g., in compositions or in pharmaceutical compositions) for administering and treating (e.g., diseases such as head and neck squamous cell carcinoma (HNSCC), cancer, blood disorders, etc.). Additional embodiments provide synergistic combinations of a BCL2 inhibitor with an IRAK inhibiting compound, and methods of using same.